











Epidemiology and biostatistics

CRO IN NUMBERS

New Clinical trial/year

Hospitalizations

Publications

Patents

Spin off

Commercial products

12 Industrial research projects

In 2018 200 clinical-experimental protocols (profit and non-profit) were active in collaboration with pharmaceutical and diagnostic industries.

In 2018 CRO's staff included 653 people (of whom 109 physicians) and 90 young research fellows. CRO hosts on average 30 residents in medical oncology and other relevant disciplines and 30 PhD students.

In 2017 CRO Campus hosted the Technology Transfer first School addressed to researchers from Italian IRCCS.

NEW PROJECTS

Biomarker for platinum treatment against different cancer types

Factors affecting sensitivity to MDM2 inhibitors in TP53 wild type tumors



Chemotherapy: Irinotecan/Imatinib Università drug monitoring

Clinical decision support tool Software to guide therapy selection and dosage with pharmacogenetic information

UP-COMINGS

New biomarkers identification and related assays development

Car-T development

AREAS OF INTEREST

Tumor genetics and biology

Hematological neoplasias

Solid tumors

Infectious agents associated tumors

Cancer epidemiology and prevention

EXPERTISE AND FACILITIES

Sequencing Functional Genomics Gene/microRNA expression profiling **Epigenetics**

Proteomic analyses

Cytofluorimetry

Microscopy and Imaging

Spectroscopy

Pre-clinical cancer model in- vivo (animal facility) Pre-clinical cancer model in-vitro Tissue Biobank

Pathological anatomy

Nanomedicine

Bioengineering

Bioimmunotherapy Cell Therapy program/Cell Factory (available in 3 years) Radiotherapy and Imaging Diagnostic

CRO's Technology Transfer Office is supported by a grant from the Italian Patent and Trademark Office (UIBM-MISE) and participates to NETVAL and ASTP-PROTON networks that BRIDGE PUBLIC RESEARCH AND INDUSTRY.



Ministero dello Sviluppo Economico







Phone 0434659749